Increased Mortality in Patients with Bullous Pemphigoid: A Nationwide Population-based Cohort Study of 5,738 Patients in Sweden
DOI:
https://doi.org/10.2340/actadv.v106.44309Keywords:
Bullous pemphigoid, autoimmune blistering disease, mortality, autoimmune subepidermal bullous disease, public health, epidemiologyAbstract
Bullous pemphigoid (BP) is the most common autoimmune blistering disease and has been linked to increased mortality, although previous studies have generally relied on small populations and no data have been available specifically for the Swedish population. This study aimed to evaluate the 1- and 10-year mortality rates and all-cause mortality in Swedish patients with BP compared with the general population. Using the National Patient Register, we conducted a retrospective cohort study and identified all BP cases in Sweden from 1 January 2005, to 31 December 2016. Age, sex, and county of residence matched controls without BP were drawn from the general population, and mortality data were obtained from the Swedish Cause of Death Register. In total, 5,738 patients with BP and 17,167 controls were included. BP patients had a significantly higher all-cause mortality (HR 2.15, 95% CI 2.06–2.24) than controls, with 1- and 10-year mortality rates of 21.2% and 80.2%, respectively. Cardiovascular diseases accounted for the largest proportion of deaths (25.3%). Notably, improved survival was observed among BP patients treated with methotrexate (MTX), prednisolone, and potent topical corticosteroids (HR 0.76, 95% CI 0.69–0.83). To our knowledge, this is the first nationwide Swedish study on BP mortality and one of the largest to date, confirming a significantly increased mortality risk in BP patients, particularly due to cardiovascular causes, while also suggesting that combined MTX, prednisolone, and potent topical steroid treatment may improve survival outcomes.
Downloads
References
Zillikens D, Wever S, Roth A, Weidenthaler-Barth B, Hashimoto T, Bröcker EB. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 1995; 131: 957–958. DOI: https://doi.org/10.1001/archderm.1995.01690200097021
Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131: 48–52. DOI: https://doi.org/10.1001/archderm.1995.01690130050009
Hertl M. Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int Arch Allergy Immunol 2000; 122: 91–100. DOI: https://doi.org/10.1159/000024364
Stanley JR. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol 1993; 53: 291–325. DOI: https://doi.org/10.1016/S0065-2776(08)60503-9
Di Zenzo G, Marazza G, Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol 2007; 23: 257–288. DOI: https://doi.org/10.1016/j.yadr.2007.07.013
Brick KE, Weaver CH, Lohse CM, et al. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol 2014; 71: 92–99. DOI: https://doi.org/10.1016/j.jaad.2014.02.030
Försti AK, Jokelainen J, Timonen M, Tasanen K. Increasing incidence of bullous pemphigoid in Northern Finland: a retrospective database study in Oulu University Hospital. Br J Dermatol 2014; 171: 1223–1226. DOI: https://doi.org/10.1111/bjd.13189
Persson MSM, Harman KE, Vinogradova Y, et al. Incidence, prevalence and mortality of bullous pemphigoid in England 1998–2017: a population-based cohort study. Br J Dermatol 2021; 184: 68–77. DOI: https://doi.org/10.1111/bjd.19022
Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 2012; 132: 1998–2004. DOI: https://doi.org/10.1038/jid.2012.35
Thorslund K, Seifert O, Nilzén K, Grönhagen C. Incidence of bullous pemphigoid in Sweden 2005–2012: a nationwide population-based cohort study of 3761 patients. Arch Dermatol Res 2017; 309: 721–727. DOI: https://doi.org/10.1007/s00403-017-1778-4
Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 2004; 122: 1091–1095. DOI: https://doi.org/10.1111/j.0022-202X.2004.22504.x
Roujeau JC, Lok C, Bastuji-Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998; 134: 465–469. DOI: https://doi.org/10.1001/archderm.134.4.465
Fine JD. Management of acquired bullous skin diseases. N Engl J Med 1995; 333: 1475–1484. DOI: https://doi.org/10.1056/NEJM199511303332207
Korman NJ. Bullous pemphigoid: the latest in diagnosis, prognosis, and therapy. Arch Dermatol 1998; 134: 1137–1141.
Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2022; 36: 1689–1704. DOI: https://doi.org/10.1111/jdv.18220
Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24: 659–667. DOI: https://doi.org/10.1007/s10654-009-9350-y
Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11: 450. DOI: https://doi.org/10.1186/1471-2458-11-450
Grönhagen C, Nilzén K, Seifert O, Thorslund K. Bullous pemphigoid: validation of the national patient register in two counties in Sweden, 2001 to 2012. Acta Derm Venereol 2017; 97: 32–35. DOI: https://doi.org/10.2340/00015555-2456
Brooke HL, Talbäck M, Hörnblad J, et al. The Swedish cause of death register. Eur J Epidemiol 2017; 32: 765–773. DOI: https://doi.org/10.1007/s10654-017-0316-1
Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726–735. DOI: https://doi.org/10.1002/pds.1294
Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180. DOI: https://doi.org/10.1136/bmj.a180
Bernard P, Enginger V, Venot J, Bedane C, Bonnetblanc JM. Pronostic vital de la pemphigoide. Analyse d’une cohorte de 78 malades. Ann Dermatol Venereol 1995; 122: 751–757.
Garcia-Doval I, Conde Taboada A, Cruces Prado MJ. Sepsis associated with dermatologic hospitalization is not the cause of high mortality of bullous pemphigoid in Europe. J Invest Dermatol 2005; 124: 666–667. DOI: https://doi.org/10.1111/j.0022-202X.2005.23628.x
Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 2005; 141: 691–698. DOI: https://doi.org/10.1001/archderm.141.6.691
Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002; 138: 903–908. DOI: https://doi.org/10.1001/archderm.138.7.903
Doffoel-Hantz V, Sparsa A, Marin B, Durox H, Bonnetblanc JM, Bédane C. Profil évolutif des patients atteints de pemphigoïde bulleuse au cours de la première année de traitement. Ann Dermatol Venereol 2009; 136: 407–411. DOI: https://doi.org/10.1016/j.annder.2009.01.009
Försti AK, Jokelainen J, Timonen M, Tasanen K. Risk of death in bullous pemphigoid: a retrospective database study in Finland. Acta Derm Venereol 2016; 96: 758–761.
Kridin K, Shihade W, Bergman R. Mortality in patients with bullous pemphigoid: a retrospective cohort study, systematic review and meta-analysis. Acta Derm Venereol 2019; 99: 72–77. DOI: https://doi.org/10.2340/00015555-2930
Bardazzi F, Filippi F, Chessa MA, et al. Mortality and prognostic factors in patients with bullous pemphigoid: a retrospective multicenter Italian study. J Eur Acad Dermatol Venereol 2022; 36: 2473–2481. DOI: https://doi.org/10.1111/jdv.18441
Shen WC, Chiang HY, Chen PS, Lin YT, Kuo CC, Wu PY. Risk of all-cause mortality, cardiovascular disease mortality, and cancer mortality in patients with bullous pemphigoid. JAMA Dermatol 2022; 158: 167–175. DOI: https://doi.org/10.1001/jamadermatol.2021.5125
Cai SC, Allen JC, Lim YL, Chua SH, Tan SH, Tang MB. Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre. Br J Dermatol 2014; 170: 1319–1326. DOI: https://doi.org/10.1111/bjd.12806
Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid: a case-control study. Arch Dermatol 1996; 132: 272–276. DOI: https://doi.org/10.1001/archderm.1996.03890270044006
Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011; 131: 637–643. DOI: https://doi.org/10.1038/jid.2010.301
Kibsgaard L, Rasmussen M, Lamberg A, Deleuran M, Olesen AB, Vestergaard C. Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br J Dermatol 2017; 176: 1486–1491. DOI: https://doi.org/10.1111/bjd.15405
Brown A, Bernier G, Mathieu M, Rossant J, Kothary R. The mouse dystonia musculorum gene is a neural isoform of bullous pemphigoid antigen 1. Nat Genet 1995; 10: 301–306. DOI: https://doi.org/10.1038/ng0795-301
Li L, Chen J, Wang B, Yao Y, Zuo Y. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 2009; 160: 1343–1345. DOI: https://doi.org/10.1111/j.1365-2133.2009.09122.x
Kridin K, Bieber K, Vorobyev A, Moderegger EL, Hernandez G, Schmidt E, et al. Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids. Br J Dermatol 2024; 191: 539–547. DOI: https://doi.org/10.1093/bjd/ljae219
Karakioulaki M, Eyerich K, Patsatsi A. Advancements in bullous pemphigoid treatment: a comprehensive pipeline update. Am J Clin Dermatol 2024; 25: 195–212. DOI: https://doi.org/10.1007/s40257-023-00832-1
Williams HC, Wojnarowska F, Kirtschig G, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 2017; 389: 1630–1638. DOI: https://doi.org/10.1016/S0140-6736(17)30560-3
Wojtczak M, Nolbrzak A, Woźniacka A, Żebrowska A. Can methotrexate be employed as monotherapy for bullous pemphigoid? analysis of efficiency and tolerance of methotrexate treatment in patients with bullous pemphigoid. J Clin Med 2023; 12: 1638. DOI: https://doi.org/10.3390/jcm12041638
Leisti P, Pankakoski A, Jokelainen J, Varpuluoma O, Huilaja L, Panelius J, et al. Accurate diagnosis of bullous pemphigoid requires multiple health care visits. Front Immunol 2023; 14: 1281302. DOI: https://doi.org/10.3389/fimmu.2023.1281302
Downloads
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2026 Zeyad Albadri, Henrike Häbel, Kristofer Thorslund, Carina Grönhagen, Oliver Seifert
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
